CANSINOBIO (06185) announced that at the board meeting held on September 26, 2025, the directors resolved to recommend: (i) the adoption of the 2025 A-Share Incentive Plan and the proposed issuance of restricted shares under the plan; (ii) the adoption of the 2025 A-Share Incentive Plan Assessment Management Measures; (iii) authorization to the board of directors to handle matters related to the 2025 A-Share Incentive Plan; (iv) the adoption of the 2025 H-Share Option Plan; (v) authorization to the board of directors to handle matters related to the 2025 H-Share Option Plan; (vi) the proposed grant of H-share options under the 2025 H-Share Option Plan; and (vii) the cancellation of repurchased A-shares and reduction of registered capital. All the above matters are subject to shareholders' approval by way of special resolutions at an extraordinary general meeting (except for the grant of H-share options to Dr. Zhu Tao, Dr. Shou Bai CHAO and Dr. Dongxu QIU under the 2025 H-Share Option Plan).

The company will convene an extraordinary general meeting to consider and, if thought fit, approve (among other things): (i) the proposed adoption of the 2025 A-Share Incentive Plan and the proposed issuance of restricted shares under the plan; (ii) the proposed adoption of the 2025 A-Share Incentive Plan Assessment Management Measures; (iii) the proposed authorization to the board of directors to handle matters related to the 2025 A-Share Incentive Plan; (iv) the proposed adoption of the 2025 H-Share Option Plan; (v) the proposed authorization to the board of directors to handle matters related to the 2025 H-Share Option Plan; (vi) the proposed grant of 371,300 H-share options to Dr. Xuefeng YU; and (vii) the proposed cancellation of repurchased A-shares and reduction of registered capital.